Topic Archives: cardiovascular disease

What’s Curzio’s “The End of Heart Disease” Stock and its “One Simple Device?”

Frank Curzio’s latest ad for his Curzio Research Advisory newsletter ($79/yr) starts out with a pretty big promise… “There’s a one-in-three chance someone you know could be saved by this new device. “That’s because one in three Americans will die due to cardiovascular disease – the No.1 killer not only in America, but worldwide.” And […]

Comments

  • Avatar

    Pharmageddon Forty years ago Ancel Keys2 sold the concept of the cholesterol etiology of cardiovascular disease, an...

  • Avatar

    I think the egg debate is definitely inconclusive at this point. As a pathologist who has cut through calcified atherosc...

  • Gr8Full!

    $RKDA - Arcadia Biosciences Achieves Key Resistant Starch Wheat Technology Milestones, Prepares for Commercial Launch ...

  • Gr8Full!

    $ESPR - Upcoming Milestones March 2018: Top-line results expected from the pivotal Phase 3 Study 4 (10...

  • Avatar

    $RVX sp Previously mentioned on SGS. Resverlogix is up 20% today Resverlogix Repays $68.8 Million Loan 12/06/2017 7...

  • Avatar

    I haven't seen this one here before. (Caution long post) miRagen $MGEN $7.75 np yet -- don't know enough about micr...

  • Avatar

    #MetFormin Larry this has all you need --see page 4 MetFormin Prevents Cardiovascular Disease and footnote 28. This has...

  • Avatar

    The most common types of cardiovascular disease include hypertension, ischemic heart disease, cerebrovascular disease (s...

  • Avatar

    I've never heard of antidepressants being implicated in overdose deaths when combined with opiates and can't really see ...

  • Avatar

    $ESPR $AMGN #PCSK9 Amgen got another round of good news for its PCSK9 franchise drug Repatha. Hot on the heels of a m...

  • Avatar

    An interesting article fresh from the press of Lancet (1/11/2017) "Study unveils how stress may increase risk of hear...

  • Dr. KSS MD PhD

    One hopes that, based on this interesting new study, bempedoic acid may have another avenue in which to shine: that of s...

  • Avatar

    What did you think about the quote in the N Y Times (about a decade ago?), where the President of the college of cardio...

  • Michael Jorrin,

    My criticism of Dr Bereliani is based not just on the dubious merit of his supplement, but on his more basic disregard o...

  • Avatar

    $ESPR Abstract: Esperion Therapeutics is developing bempedoic acid to treat cardiovascular disease and to help those t...

  • SoGiAm

    #Pharmacogenomics Finds Aspirin-Responsive RUNX1 TF Linked to #Cardiovascular Disease and Colon #Cancer via @CastlDalmun...

  • arch1

    Radiation caused cardiovascular disease my put brakes on deep space exploration; http://www.airspacemag.com/daily-pla...

  • Avatar

    Here is a more detailed article on LPCN in regards to liver toxicity. http://endocrinenews.endocrine.org/new-researc...

  • Dr. KSS MD PhD

    New paper vigorously doubting the cholesterol hypothesis of cardiovascular disease: Full text: http://bmjopen.bmj.com...

  • Avatar

    Interesting article on liver causing heart disease or cancer: A UCF College of Medicine researcher has identified for ...

  • SoGiAm

    $ARWR-Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after ...

  • Avatar

    Sorry link did not take. Celyad notifies the European Medicines Agency (EMA) of its intention to file a Marketing Aut...

  • Avatar

    Celyad initiates the certification by the EMA of the non-clinical data of C-Cure® Mont-Saint-Guibert, Belgium - Cely...

  • Avatar

    ABIO leveraging genetic targeting to better treatment of Cardiovascular Disease. http://finance.yahoo.com/news/arca-bio...

  • Avatar

    From Biotech Watcher (Alan Leong)As profiled in their recent announcement and conference call, Esperion’s ETC-1002 wa...

  • Avatar

    $ESPR This is the best part of the Esperion FDA feedback: "Based on feedback from the FDA, approval of ETC-1002 in ...

  • Avatar

    From Alan Hobbes re: $ESPR Esperion (ESPR) Dives 20% in Response to Lackluster Label for PCSK9 Drug Approval On Thurs...

  • sogiam

    TRVN-Trevena Appoints Yacoub Habib as Senior Vice President, Business Development and Corporate Planning KING OF PRUS...

  • Avatar

    This reminds me of Resveralogix (RVX on TSX) which has a unique small molecule approach getting into Phase 3 trials, tha...

  • DBMD

    ABIO (mentioned Tiny BioTech) Lots of news accounting for uptick rNAPc2 Previously Demonstrated Post-Exposure Efficacy...

  • Avatar

    I just discovered that one can get free updates via email on almost all FDA topices at http://www.fda.gov/AboutFDA/Cont...

  • Avatar

    Here is an encouraging news release from ISIS (Benitec's foster parent): CARLSBAD, Calif., Sept. 2, 2014 /PRNewswire/...

  • Avatar

    DR. Kss: In line with your thinking: Top NewsLatest A statin a day to keep the doctor away? comparing aspirin and sta...

  • Avatar

    Have been through Medical Wonderland since 1992 when I blew out half my parietal lobe with my first major stroke. My me...

  • Avatar

    Hmm. I didn't know what "unraveled" meant in "The study carried out at the University of Sydney in Australia unraveled ...

  • Avatar

    Science (in the form off independently funded randomised controlled trials with statistically significant results) tells...

  • Avatar

    #1051 Glen. I own ISR. So does SABBY a biotech focused investment house. Link to feel good article: Benny Tech all ...

  • karma swim swami

    I am aware of all these "findings." Anatabine for rosacea? How is that relevant for cardiovascular disease? CRP, a glob...

  • Michael Jorrin (aka Doc Gumshoe)

    Thanks for all the comments - can't reply in detail since we're off to Maine for a little vacation. BUT - re chelation...

  • Avatar

    I agree, Resveratrol is not necessarily the magic ingredient in wine. Small amounts of ethanol may be. You probably ...

  • Avatar

    Cholesterol lowering drugs are undoubtedly effective and here to stay but are not really getting at the root cause of c...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch